Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iscalimab versus placebo in pediatric and young adult patients with new-onset type 1 diabetes mellitus
2018-004553-25Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing Iscalimab with Placebo (2 arms). Primary endpoint: Proportion of subjects with adverse events and serious adverse events. Started Jun 2019; status: completed.
02
Drugs
iscalimab
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2018-004553-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004553-25.